Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingTrial watch - inhibiting PARP enzymes for anticancer therapyReaders of poly(ADP-ribose): designed to be fit for purposeDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerSuccesses and Challenges of PARP Inhibitors in Cancer TherapyEvaluation and Structural Basis for the Inhibition of Tankyrases by PARP InhibitorsDiscovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 InhibitorsAnother "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug SensitivityA phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyEssential versus accessory aspects of cell death: recommendations of the NCCD 2015.Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage.Imaging the DNA damage response with PET and SPECTKynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsPharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.Effects of Poly(ADP-Ribose) Polymerase-1 Inhibition in a Neonatal Rodent Model of Hypoxic-Ischemic Injury.Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytesRegulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.Increased DNA damage in progression of COPD: a response by poly(ADP-ribose) polymerase-1.A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.An update on PARP inhibitors for the treatment of cancerRandomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerNew paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the NucleusPARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell functionPoly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axisDifferential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage.BRCA1 Mutation: A Predictive Marker for Radiation Therapy?Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoPARP1 Inhibitors: antitumor drug design.Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.Chemical Methods for Encoding and Decoding of Posttranslational ModificationsInduction of Poly(ADP-ribose) Polymerase in Mouse Bone Marrow Stromal Cells Exposed to 900 MHz Radiofrequency Fields: Preliminary Observations.
P2860
Q23923997-1728AD00-0B1B-4074-BCB4-E0913BB3FAA2Q26745673-D2C9E45F-9D02-478D-96B4-5F870C6A98F4Q26775561-8B09596F-2BC4-47FB-A995-1F1529F794F7Q26776513-8A4AAADC-1EFE-407B-8C03-477E9BFD7DB8Q26777131-8AD0B8C1-97F4-4FBD-8CA7-C7AC563276A7Q27684215-D3F9F2AF-B6A1-4DCC-A6F6-D326E66FD155Q27684311-27FBEE2D-EA96-45ED-8264-429E03D04DB0Q28543952-13AD19F6-0661-40AE-A183-690708C84449Q28545860-3A35CF19-23D9-4156-81A6-D0C85140AC6AQ30277998-2B8BF015-4207-4C06-84EC-D85954F608F1Q30408769-965A29DE-2CA4-48F6-A3EA-3A7A4506E561Q30830820-3BC3BAE4-3ECC-4ADE-83A3-C2384096C751Q33558275-1CB56C52-D2B6-4792-8354-05D821109A7DQ33581909-1E2C16B2-A617-448F-A2EE-D81795CF3B3CQ33583816-8A6ADD53-B6D3-4DCB-9537-AA7A246FF9A7Q33603605-535E1A8E-781E-4A17-A7CA-A537A10C5C99Q33618910-8F5053A7-8153-4858-B775-52C3B2B4294EQ33717621-B9916BEA-0DB4-4567-97EC-033B2D08230AQ33862270-F2E46044-45AA-4DB8-B931-A96DD44CC7DCQ34129753-CB3D97F6-9C8A-40EE-A45A-AFA203ED8401Q34186029-6218D8E4-BD4B-49FA-9DB3-2D098E071707Q34876209-F18919EE-EF5C-40CA-9BF3-0B145FCC56EDQ35055636-C79E3A90-B667-4617-A29D-D886246CF984Q35092269-7EA54467-57DE-4764-A6AC-F665DA446FD0Q35142718-F400A424-3FBB-4BC6-9065-EFDE8B10173EQ35251489-51E56601-7E56-4328-BDCF-04C70AC78129Q35395549-7E204B73-2ADE-4FC7-B774-21783CA37BEDQ35720459-0F1AF668-F69D-4B6F-AC21-F47FC60973B8Q35799917-C1510756-47A4-4790-BAB1-876C8267AFEAQ35805959-CEA8333E-12EB-4DA4-A30E-3E25331ADD4CQ35848889-1B3BF0F1-B7BB-459E-A29A-9099424B6B99Q35857399-F449E89B-6BA9-42F6-9AF3-7868F3F7F752Q36076728-E11630A2-172C-44B9-8A56-E1556C318E23Q36076772-F4D36A2B-5159-4755-B821-167F7491A781Q36160278-16784530-A825-4FE6-BFA6-80FA569917DEQ36175159-A2DCCD6F-689F-49F1-9A31-70A72C32CE62Q36259861-CE90806F-1B23-4C4C-AF2A-2E65882994A8Q36562360-BA7134DE-E045-4314-8C66-5EE08EA88850Q36654176-EDB3154D-4CB3-4A1A-ACCC-DE3C88972EA8Q36845495-2ADB4C64-D8E7-4582-A368-4C95CBF49A54
P2860
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
@en
type
label
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
@en
prefLabel
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
@en
P2860
P1476
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
@en
P2093
Csaba Szabo
Nicola J Curtin
P2860
P304
P356
10.1016/J.MAM.2013.01.006
P577
2013-01-29T00:00:00Z